Thu.Oct 03, 2024

article thumbnail

Eli Lilly's shortage of diabetes and obesity drugs is over, halting competition with knock-offs

Fierce Pharma

Eli Lilly’s juggernaut diabetes and obesity drugs Mounjaro and Zepbound have been erased from the FDA’s shortage list, | Eli Lilly’s juggernaut diabetes and obesity drugs Mounjaro and Zepbound have been erased from the FDA’s shortage list, freeing the company from competing with compounding pharmacies that have been producing copycat versions of the in-demand treatments.

article thumbnail

First Do No Harm: Support Legislative Efforts to Combat the Adverse Drug Event Epidemic 

MedCity News

The Hippocratic oath can’t stop with direct patient care; the healthcare industry and its key stakeholders must address persistent public health problems systematically. We have the tools to reduce medication harm by half or more; it is long past time to make this a public health priority. The post First Do No Harm: Support Legislative Efforts to Combat the Adverse Drug Event Epidemic appeared first on MedCity News.

Medical 125
Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Trending Sources

article thumbnail

For Bristol Myers Squibb's newly approved schizophrenia drug, what a long, strange trip it's been

Fierce Pharma

On its way to becoming the most highly anticipated approval of 2024, BMS’ schizophrenia treatment Cobenfy has had an unusual but instructive odyssey.

281
281
article thumbnail

Funding In Youth Mental Health Is Growing. Where are the Opportunities?

MedCity News

More investors are becoming interested in digital health startups specifically targeting youth behavioral health. However, there are still more opportunities to reach youth on Medicaid. The post Funding In Youth Mental Health Is Growing. Where are the Opportunities? appeared first on MedCity News.

114
114
article thumbnail

From Diagnosis to Delivery: How AI is Revolutionizing the Patient Experience

Speaker: Simran Kaur, Founder & CEO at Tattva Health Inc.

The healthcare landscape is being revolutionized by AI and cutting-edge digital technologies, reshaping how patients receive care and interact with providers. In this webinar led by Simran Kaur, we will explore how AI-driven solutions are enhancing patient communication, improving care quality, and empowering preventive and predictive medicine. You'll also learn how AI is streamlining healthcare processes, helping providers offer more efficient, personalized care and enabling faster, data-driven

article thumbnail

BMS' Opdivo joins the perioperative lung cancer treatment ring with key FDA approval

Fierce Pharma

Hot on the tail of AstraZeneca’s Imfinzi, Bristol Myers Squibb’s PD-1/L1 inhibitor Opdivo has expanded its non-small cell lung cancer (NSCLC) net with an

FDA 273
article thumbnail

AAPS PharmSci 360 2024: Drug Delivery in Early Development

PharmaTech

Pharmaceutical Technology sat down with Erica Schlesinger, vice president of technical development at Serán Bioscience, to talk about her upcoming presentation at AAPS PharmSci 360 2024, “High Dose Subcutaneous Delivery of Protein Therapeutics.

More Trending

article thumbnail

Gilead strikes deal to expand HIV drug access in 120 countries

pharmaphorum

Gilead has partnered with six generic manufacturers to expand access to HIV Drug lenacapavir in high-incidence, resource-limited countries following promising clinical trial results.

article thumbnail

WuXi service providers weigh sales of certain assets amid BIOSECURE scrutiny: FT

Fierce Pharma

As the BIOSECURE Act works its way through the U.S. legislative branch, two companies named in the bill are reportedly weighing sales of certain units and facilities. | WuXi AppTec has put its cell and gene therapy manufacturing arm, WuXi Advanced Therapies, on the market, The Financial Times reported Thursday. At the same time, WuXi Biologics is working with advisors to gauge interest in some of its European production facilities, the news outlet added, citing sources.

Sales 232
article thumbnail

How Can AI Startups Navigate Healthcare’s Fragmented Landscape?

MedCity News

AI startups should be thoughtful about which healthcare market(s) they’re going after, according to investors at Bessemer Venture Partners. Healthcare AI startups seeking venture capital face heightened expectations for scale, which requires access to substantial total addressable markets. The post How Can AI Startups Navigate Healthcare’s Fragmented Landscape?

article thumbnail

Ferring opens doors to Finnish manufacturing hub as supply of its bladder cancer gene therapy continues to grow

Fierce Pharma

After unlocking commercial supply and enlisting a manufacturing partner earlier this year, Ferring Pharmaceuticals has reached a new turning point on its quest to satisfy current and future demand | Ferring on Thursday opened a new global manufacturing hub in Kuopio, Finland, to help produce drug substance for Adstiladrin, which was approved by the FDA in late 2022 as the first gene therapy to target high-risk and non-muscle invasive bladder cancer in patients who no longer respond to therapy.

article thumbnail

Increase Revenue With Better, Faster Sales Onboarding

Quotas need to be hit. Revenue goals need to be met. This reality makes shortening sales onboarding time a top priority. Organizations with a standard onboarding process boost employee retention by 58% and increase productivity by 50%. Unfortunately, many companies struggle with inefficient processes that lead to high turnover and missed revenue opportunities.

article thumbnail

CBRE Report: Post-Pandemic Slowdown Now Evident in Oversupply of Biotech Labs

MedCity News

Laboratory construction has waned in the past two years due to the end of the pandemic and an economic slowdown, according to a new report from CBRE. The firm predicts in-progress lab construction will decline to pre-pandemic levels by 2026. The post CBRE Report: Post-Pandemic Slowdown Now Evident in Oversupply of Biotech Labs appeared first on MedCity News.

Biopharma 101
article thumbnail

NHS England proposes phased rollout for Eli Lilly's star obesity drug

Fierce Pharma

As officials consider how to distribute Eli Lilly’s Mounjaro to a nation that has a rapidly growing (PDF) o | As officials consider how to distribute Eli Lilly’s Mounjaro to a nation that has a rapidly growing obesity problem, England’s National Health Service is proposing that those who need it most should get it first.

article thumbnail

Shock, Fear and Anxiety – The Complexity of Breast Cancer Beyond Diagnosis

MedCity News

Providers should incorporate mental health screenings as a standard part of cancer care for patients and their loved ones. The post Shock, Fear and Anxiety – The Complexity of Breast Cancer Beyond Diagnosis appeared first on MedCity News.

article thumbnail

Fierce Pharma Asia—Roche's $850M-plus deal with Regor; Legend's busy week; WuXi firms' asset sale?

Fierce Pharma

On the same day as Roche's Pharma Day in London, the biopharma giant revealed a high-dollar deal with Chinese-American biotech Regor for the latter's CDK inhibitors. | On the same day as Roche's Pharma Day in London, the drugs giant struck a high-dollar deal with Chinese-American biotech Regor for the latter's CDK inhibitors. Legend's momentum continued with a strong survival showing for Johnson & Johnson-partnered Carvykti and the announcement of a planned R&D f

Pharma 200
article thumbnail

Optimizing Clinical Supply Strategy: Navigating Challenges & Finding Your Ideal Model

article thumbnail

Social media algorithms are driving the GLP-1 drugs boom

Pharmaceutical Technology

GLP-1 RAs are being recommended on social media, raising questions about who can see the content and what the effects might be.

Media 105
article thumbnail

Argenx widens its Halozyme Therapeutics-partnered net with 4 new targets in $30M license expansion

Fierce Pharma

With a recently acquired FDA nod for its Halozyme Therapeutics-partnered Vyvgat Hytrulo, argenx is looking to take Halozyme’s delivery tech to new heights through a $30 million licensing deal that | The company's collaboration with drug delivery partner Halozyme Therapeutics now totals six targets and could result in milestone payments of up to $85 million per target for Halozyme.

FDA 199
article thumbnail

Social media algorithms are driving the the GLP-1 drugs boom

Pharmaceutical Technology

GLP-1 RAs are being recommended on social media, raising questions about who can see the content and what the effects might be.

Media 98
article thumbnail

Beyond the Buzzword: Unlocking the Power of Omnichannel in Pharma

Fierce Pharma

Omnichannel marketing has proven itself as a powerful strategy across industries, and healthcare and pharma are no excep | In this insightful episode, we sit down with Jaclene Johnson, Vice President at Tandem, a leading precision healthcare marketing technology firm, to explore how omnichannel can be effectively harnessed by professionals in the healthcare space.

Pharma 130
article thumbnail

Using Generative AI in Sales: Pros, Cons, and Considerations According to Sellers

Are your sellers unsure about using AI in their day-to-day workflows? Or are they eager to try but uncertain where to start? They might be asking: Which tasks are best suited for AI? How will using AI affect my relationship with my customers? With so many tools available, which ones are the most useful to me? To help answer these and other common questions about using AI during the sales cycle, we surveyed B2B sellers who were early adopters to get their insight and advice about how to use gen A

article thumbnail

AI pathology accelerates with Proscia Concentriq launch

pharmaphorum

Proscia announces launch of Concentriq Embeddings and Proscia AI Toolkit, hoping to accelerate precision medicine R&D.

article thumbnail

Transforming Pharma Marketing: Insights on AI and Brand-Building from Biophonic Communication

Fierce Pharma

“I’m sure if you were to sit anybody else in this chair, they lead with AI. I will too,” said Steven Carickhoff, president of BioPharm Communications, at Digital Pharma East. | In this interview, the President of Biophonic Communication discusses how AI is transforming clients’ commercial models by improving data integration, speeding up product launches, and identifying key therapeutic areas.

Pharma 130
article thumbnail

Investment outlook: Key takeaways from LSX USA

pharmaphorum

Discover the key takeaways from the LSX USA Congress with this podcast wrap-up, offering insights into investment outlook and trends discussed at the event.

86
article thumbnail

The Direct-to-Patient Platform: Transforming the Patient Journey for Better Outcomes

Fierce Pharma

Matthew Walsh, General Manager of Biopharma at ixlayer - the leading cloud-based platform powering an end-to-end, direct-to-patient healthcare solution - sat down with Fierce at Digital Phar | Matthew Walsh, General Manager of Biopharma at Ixlayer – a cloud-based platform specialist empowering operational efficiency, patient access, and improved outcomes – sat down with Fierce at Digital Pharma East.

Patients 130
article thumbnail

European Clinical Supply Planning: Balancing Cost, Flexibility and Time

article thumbnail

Research shows NHS, industry partnership benefits patients

pharmaphorum

A new report commissioned by ABPI found hospitals engaging in industry partnerships more likely to follow NICE recommendations.

article thumbnail

Tapping the Value of Conscientious Stewardship

Pharmaceutical Commerce

Why it's critical for companies to set long-term, strategic goals in their journeys toward decarbonization.

97
article thumbnail

IRLAB’s new drug shows promise in treating apathy in Parkinson’s patients

PharmaTimes

Phase 1 trial of IRL757 demonstrates good absorption and safety profile

Safety 104
article thumbnail

European manufacturing facility to strengthen gene therapy supply

European Pharmaceutical Review

Ferring Pharmaceuticals has opened a new European manufacturing site focused on supporting production for one of its gene therapies to treat non-muscle invasive bladder cancer (NMIBC). The global manufacturing hub in Kuopio, Finland will bolster supply of the drug substance of its gene therapy Adstiladrin ® (nadofaragene firadenovec-vncg). The treatment is the first and only US Food and Drug Administration (FDA)-approved intravesical non-replicating gene therapy for adults with high-risk Bacillu

article thumbnail

How Machine Learning Drives Clinical Trial Efficiency

Clinical trial data management is increasingly challenging as studies grow in complexity. Quickly accessing and analyzing study data is vital for assessing trial progress and patient safety. In this paper, we explore real-time data access and analysis for proactive study management. We investigate using adverse event (AE) data to monitor safety and discuss a clinical analytics platform that supports collaboration and data review workflows.

article thumbnail

ERLEADA shows 23% survival benefit over enzalutamide in prostate cancer study

PharmaTimes

Largest real-world study demonstrates significant survival advantage

96
article thumbnail

European Pharmaceutical Review Issue 4 2024

European Pharmaceutical Review

Articles in Issue 4 of European Pharmaceutical Review include: FOREWORD The FDA’s new mandate on Burkholderia cepacia complex (BCC) testing: implications for non-sterile drug products Dave Elder David P Elder Consultancy REGULATORY INSIGHT ECCTA: cracking down on fraud in the life sciences sector Quinton Newcomb and Farheen Ishtiaq-Stansfeld Fieldfisher ENVIRONMENTAL MONITORING Best practices in environmental monitoring of compressed gas ports Ryan Brough, Peter Lisowski and Alicia Vieau C

article thumbnail

Behind the Headlines: Sickle Cell Therapies; Mpox Vaccines; and ARCH Ventures’ Biotech Fund

PharmaTech

This Behind the Headlines news roundup panel discussion on recent news items includes updates regarding sickle cell therapies (e.g,, Pfizer’s withdrawal of Oxbryta and Vertex’s choosing of Lonza as the commercial manufacturer of Casgevy); Emergent BioSolutions $400 million BARDA contract for an mpox vaccine; and the first in a generation novel schizophrenia drug, Cobenfy (xanomeline and trospium chloride).

article thumbnail

Pharmaceutical Marketing Strategies: How to Effectively Promote Your Brand

Pharma Marketing Network

In the competitive landscape of the pharmaceutical industry, effective marketing strategies are crucial for brand success. Pharmaceutical marketing is not just about reaching healthcare professionals and patients; it involves a complex interplay of understanding market dynamics, regulatory compliance, and leveraging digital platforms. This article explores key strategies for promoting pharmaceutical brands, providing insights into understanding market dynamics, identifying target audiences, craf

article thumbnail

Unlocking Excellence: How Catalent Is Transforming Japan’s Clinical Research

Planning on running clinical trials in Japan? How can you reliably supply these studies? Discover Catalent’s clinical supply packaging facility in Shiga, Japan. Strategically located between Tokyo and Osaka, and one of largest in Japan, this 6,000 square meter facility offers comprehensive services including primary and secondary clinical packaging and labelling, comparator sourcing, cold chain storage, local and global distribution, local language support and white glove service to support stud